Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, Earl P, Moss B, Peel S, Slike B, Sriplienchan S, Thongcharoen P, Paris RM, Robb ML, Kim J, Michael NL, Marovich MA.
Currier JR, et al. Among authors: polonis vr.
PLoS One. 2010 Nov 15;5(11):e13983. doi: 10.1371/journal.pone.0013983.
PLoS One. 2010.
PMID: 21085591
Free PMC article.
Clinical Trial.